CD4+ T cell differentiation and function in autoimmune thyroid disease and its mechanisms

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100046797

Enrollment

Unknown

Registered

2021-05-28

Start date

2021-05-28

Completion date

Unknown

Last updated

2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune thyroid disease

Interventions

AITD group:Levothyroxine treatment

Control group:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with positive TPOAb or TGAb on thyroid function tests and ultrasound showing changes consistent with Hashimoto's thyroiditis who attended Shandong Provincial Hospital from April 2021 to June 2022; patients who attended Shandong Provincial Hospital from April 2021 to June 2022 and all thyroid function tests were normal; gender and age are not required. Gender and age are not required.

Exclusion criteria

Exclusion criteria: 1.Other autoimmune diseases; 2.Hormonal or immunosuppressive drugs; 3.Thyroidectomy; 4.I131 treatmen.

Design outcomes

Primary

Measure	Time frame
Peripheral blood CD4+ T cells;Peripheral blood lymphocyte transcriptome;Thyroid function;	—

Countries

China

Contacts

Public ContactZhang Haiqing

15168888303@163.com+86 15168888303

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026